Sartorius Stedim Biotech Expands PAT Software Portolio for Optimization of Biopharmaceutical Development and Manufacturing Processes
Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, has entered into a global sales partnership with Umetrics AB, a Swedish software manufacturer.
Goettingen, Germany, December 18, 2012 / B3C newswire / – Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, has entered into a global sales partnership with Umetrics AB, a Swedish software manufacturer. Umetrics is a highly specialized, leading provider of chemometrics software worldwide for modeling and optimizing biopharmaceutical development and manufacturing processes.
The cooperation agreement provides that SSB will assume global marketing and distribution of the complete Umetrics portfolio for the pharmaceutical and biopharmaceutical industries. SSB will integrate Umetrics software programs as private label products into its own bioprocess portfolio and market these as stand-alone solutions under both brands under a dual branding arrangement. Stefan Schlack, Senior Vice President of Marketing at SSB commented: “These software solutions will help our customers to better understand their cell culture processes and to identify potential for optimization and robust process control – an ideal addition to our bioprocess portfolio.”
The major areas of application for these software systems are critical process steps, such as cell culture processes or specific purification steps in the biopharmaceutical industry. Multivariate data analysis (MVA) enables all process parameters to be added in batch trajectories, among other things, so that process variations and their causes can be displayed transparently in real time. DoE software (Design of Experiments) permits these critical process parameters to be efficiently identified and quantified and development cycles to be considerably shortened.
Umetrics stands to benefit from the global sales structures of SSB. “With SSB, we can gain access to substantially more customers thanks to its international reach and solid market standing in the biopharma sector. SSB’s integrated solutions for the complete biopharmaceutical process clearly create added value for our customers. I anticipate that this will considerably boost the biopharmaceutical industry’s interest in and usage of our products,” says Lars Lindstorm, General Manager of Umetrics.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.